Cargando…
Glucagon-like peptide-1 (GLP-1) receptor agonists: Differentiating the new medications
INTRODUCTION: Glucagon-like peptide-1 (GLP-1) has been the focus of considerable research activity in the treatment of type 2 diabetes mellitus (T2DM) because the incretin effect is significantly reduced or absent in individuals with T2DM. Thus, pharmacologic efforts to develop medications that mimi...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer Healthcare Communications
2011
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3124643/ https://www.ncbi.nlm.nih.gov/pubmed/22127767 http://dx.doi.org/10.1007/s13300-010-0013-5 |